Physician profile
Megan E Goebel
NPI 1689930695
$14,381.73
in general payments reported to CMS, 2019-2025
32 companies · $3,475 in 2025
The $3,475 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $668 · 2021: $1,105 · 2022: $2,261 · 2023: $2,684 · 2024: $2,929 · 2025: $3,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,057 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,057.27 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,398.48 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,246.43 | 2019-2025 | |
| Csl Behring | $1,374.21 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $1,274.01 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $1,158.90 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $797.72 | 2019-2025 | |
| Abbvie INC. | $711.90 | 2022-2025 | |
| Pfizer INC. | $508.07 | 2019-2025 | |
| Genentech USA, INC. | $498.98 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $365.05 | 2021-2025 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Amgen INC. | $339.86 | 2020-2025 | Tezspire, Actimmune |
| Optinose US, INC. | $271.27 | 2021-2025 | |
| Grifols USA, LLC | $231.97 | 2020-2025 | Xembify |
| Biocryst US Sales Co., LLC | $198.81 | 2023-2025 | Orladeyo |
| Kaleo, INC. | $148.26 | 2020-2023 | Auvi-Q |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $142.02 | 2025 | Neffy |
| Blueprint Medicines Corporation | $137.68 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $100.09 | 2024-2025 | Eohilia, Cuvitru |
| Teva Pharmaceuticals USA, INC. | $84.26 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $75.20 | 2023-2025 | Ryaltris, Mitigare |
| Alk-Abello, INC | $47.29 | 2023 | Pre-Pen, Alternaria Tenuis, Standardized Mite D. Farinae |
| Leo Pharma INC. | $36.90 | 2022 | |
| Insmed, INC. | $34.50 | 2025 | Arikayce |
| Covis Pharma Gmbh | $33.95 | 2022 | |
| Harmony Biosciences LLC | $28.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $27.85 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.30 | 2019 | |
| Verona Pharma, INC. | $19.78 | 2025 | Ohtuvayre |
| Avanos Medical | $16.06 | 2024 | On-Q* Pump and Accessories |
| Aimmune Therapeutics, INC. | $12.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Goebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.